HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Signatures of anti-Thomsen - Friedenreich antigen antibody diversity in colon cancer patients.

AbstractAIM:
To determine whether the structural and functional diversities of naturally occurring antibodies to the Thomsen - Friedenreich (TF) antigen may be of diagnostic and prognostic value in colon cancer.
MATERIALS AND METHODS:
Serum samples were taken from patients with colon cancer (n = 94) and healthy controls (n = 64). The level of TF-specific antibody isotypes and their sialylation were determined using ELISA and lectin-ELISA with synthetic TF-polyacrylamide conjugate as an antigen and a sialic acid-specific Sambucus nigra agglutinin (SNA). The avidity was determined using ammonium thiocyanate as a chaotrope. The accuracy of diagnostics was evaluated using the receiver operator characteristic curve analysis and the survival analysis employing the Kaplan - Meier method.
RESULTS:
Compared to healthy controls, patients with colon cancer exhibited a lower level of anti-TF IgG antibodies, significantly lower ratios of TF-specific IgG/IgM and IgG/IgA, an increased SNA reactivity of anti-TF antibodies, mostly on account of IgG, and a lower avidity of TF-specific antibodies, especially their SNA-reactive subset. An increased SNA reactivity of anti-TF IgG was observed already at the early stages of cancer (p = 0.0004). The decrease of the ratio of IgG/IgM and IgG/IgA showed a good accuracy of diagnostics with about 60% sensitivity at 90% specificity. A similar potential was found for the SNA binding/IgG level index. The high level of TF-specific IgA antibodies was associated with a lower survival rate (hazard ratio = 0.34).
CONCLUSION:
This is the first report ever on the colon cancer-related signatures of anti-TF antibody diversity which show diagnostic potential, including in early cancer, and prognostic value. The hypersialylation of TF-specific antibodies appeared to be a common phenomenon in cancer. The signatures may be used as non-invasive antibody-based markers for colon cancer.
AuthorsO Kurtenkov, M Bubina, K Klaamas
JournalExperimental oncology (Exp Oncol) Vol. 40 Issue 1 Pg. 48-58 (Mar 2018) ISSN: 1812-9269 [Print] Ukraine
PMID29600973 (Publication Type: Journal Article)
Chemical References
  • Antibodies
  • Antigens, Tumor-Associated, Carbohydrate
  • Biomarkers, Tumor
  • Thomsen-Friedenreich antigen
  • Thomsen-Friedenreich antibodies
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies (immunology)
  • Antibody Diversity
  • Antigens, Tumor-Associated, Carbohydrate (immunology)
  • Area Under Curve
  • Biomarkers, Tumor (immunology)
  • Colonic Neoplasms (diagnosis, immunology, mortality)
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • ROC Curve
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: